<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Hum Hypertens</journal-id><journal-title-group><journal-title>Journal of Human Hypertension</journal-title></journal-title-group><issn pub-type="ppub">0950-9240</issn><issn pub-type="epub">1476-5527</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21248785</article-id><article-id pub-id-type="pmc">3175529</article-id><article-id pub-id-type="pii">jhh2010115</article-id><article-id pub-id-type="doi">10.1038/jhh.2010.115</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension</article-title><alt-title alt-title-type="running">24-hour blood pressure control with triple therapy</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lacourci&#x000e8;re</surname><given-names>Y</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Crikelair</surname><given-names>N</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Glazer</surname><given-names>R D</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Yen</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Calhoun</surname><given-names>D A</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><aff id="aff1"><label>1</label><institution>Hypertension Research Unit, Centre Hospitalier Universitaire de Qu&#x000e9;bec (CHUL)</institution>, Qu&#x000e9;bec, <country>Canada</country></aff><aff id="aff2"><label>2</label><institution>Department of Cardiovascular Clinical Research &#x00026; Development, Novartis Pharmaceuticals Corporation</institution>, East Hanover, NJ, <country>USA</country></aff><aff id="aff3"><label>3</label><institution>Department of Integrated Information Science Cardiovascular and Metabolism, Novartis Pharmaceuticals Corporation</institution>, East Hanover, NJ, <country>USA</country></aff><aff id="aff4"><label>4</label><institution>Division of Pulmonary, Allergy, and Critical Care Medicine, Vascular Biology and Hypertension Program, Sleep/Wake Disorders Center, University of Alabama at Birmingham</institution>, Birmingham, AL, <country>USA</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label><institution>Hypertension Research Unit, Centre Hospitalier Universitaire de Qu&#x000e9;bec (CHUL)</institution>, 2705 Laurier Boulevard, Laurier Local S-137, Ste-Foy, Quebec, <country>Canada</country> G1V 4G2. E-mail: <email>yves.lacourciere@crchul.ulaval.ca</email></corresp></author-notes><pub-date pub-type="ppub"><month>10</month><year>2011</year></pub-date><pub-date pub-type="epub"><day>20</day><month>01</month><year>2011</year></pub-date><volume>25</volume><issue>10</issue><fpage>615</fpage><lpage>622</lpage><history><date date-type="received"><day>10</day><month>03</month><year>2010</year></date><date date-type="rev-recd"><day>29</day><month>10</month><year>2010</year></date><date date-type="accepted"><day>31</day><month>10</month><year>2010</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2011 Macmillan Publishers Limited</copyright-statement><copyright-year>2011</copyright-year><copyright-holder>Macmillan Publishers Limited</copyright-holder><license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><!--author-paid--><license-p>This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/</license-p></license></permissions><abstract><p>To determine the effectiveness and safety of once-daily combination therapy with amlodipine, valsartan and hydrochlorothiazide for reducing ambulatory blood pressure (ABP) in patients with moderate to severe hypertension, a multicenter, double-blind study was performed (<italic>N</italic>=2271) that included ABP monitoring in a 283-patient subset. After a single-blind, placebo run-in period, patients were randomized to receive amlodipine/valsartan/hydrochlorothiazide (10/320/25&#x02009;mg), valsartan/hydrochlorothiazide (320/25&#x02009;mg), amlodipine/valsartan (10/320&#x02009;mg) or amlodipine/hydrochlorothiazide (10/25&#x02009;mg) each morning for 8 weeks. Efficacy assessments included change from baseline in 24-h, daytime and night time mean ambulatory systolic BP (SBP) and diastolic BP (DBP). Statistically significant and clinically relevant reductions from baseline in all these parameters occurred in all treatment groups (<italic>P</italic>&#x0003c;0.0001, all comparisons versus baseline). At week 8, least squares mean reductions from baseline in 24-h, daytime and night time mean ambulatory SBP/DBP were 30.3/19.7, 31.2/20.5 and 28.0/17.8&#x02009;mm&#x02009;Hg, respectively, with amlodipine/valsartan/hydrochlorothiazide; corresponding reductions with dual therapies ranged from 18.8&#x02013;24.1/11.7&#x02013;15.5, 19.0&#x02013;25.1/12.0&#x02013;16.0 and 18.3&#x02013;22.6/11.1&#x02013;14.3&#x02009;mm&#x02009;Hg (<italic>P</italic>&#x02a7d;0.01, all comparisons of triple versus dual therapy). Treatment with amlodipine/valsartan/hydrochlorothiazide maintained full 24-h effectiveness, including during the morning hours; all hourly mean ambulatory SBP and mean ambulatory DBP measurements were &#x02a7d;130/85&#x02009;mm&#x02009;Hg at end point. Amlodipine/valsartan/hydrochlorothiazide combination therapy was well tolerated. Once-daily treatment with amlodipine/valsartan/hydrochlorothiazide (10/320/25&#x02009;mg) reduces ABP to a significantly greater extent than component-based dual therapy and maintains its effectiveness over the entire 24-h dosing period.</p></abstract><kwd-group><kwd>triple therapy</kwd><kwd>amlodipine</kwd><kwd>valsartan</kwd><kwd>hydrochlorothiazide</kwd></kwd-group></article-meta></front><body><sec><title>Introduction</title><p>The blood pressure (BP) surge that occurs between 6  and noon<sup><xref ref-type="bibr" rid="bib1">1</xref></sup> has been associated with a peak in the incidence of cardiovascular events and sudden death.<sup><xref ref-type="bibr" rid="bib2">2</xref></sup> This surge in BP (&#x0223c;10&#x02013;30&#x02009;mm&#x02009;Hg in systolic BP (SBP) and 7&#x02013;23&#x02009;mm&#x02009;Hg in diastolic BP (DBP))<sup><xref ref-type="bibr" rid="bib2">2</xref></sup> coincides with an increase in pulse rate and sympathetic tone and activation of the renin-angiotensin-aldosterone system.<sup><xref ref-type="bibr" rid="bib3">3</xref>, <xref ref-type="bibr" rid="bib4">4</xref>, <xref ref-type="bibr" rid="bib5">5</xref>, <xref ref-type="bibr" rid="bib6">6</xref></sup> In turn, activation of the renin-angiotensin-aldosterone system results in increased levels of aldosterone and angiotensin II, a potent vasoconstrictor that modulates vasomotor tone, cell growth and extracellular matrix deposition.<sup><xref ref-type="bibr" rid="bib7">7</xref></sup> Several studies have shown that among patients who appear to have well-controlled morning BP, as assessed by office measurements, &#x0223c;60&#x00025; have poorly controlled morning BP when assessed by ambulatory BP monitoring (ABPM).<sup><xref ref-type="bibr" rid="bib8">8</xref>, <xref ref-type="bibr" rid="bib9">9</xref></sup></p><p>It is well established that the majority of patients with hypertension require two or more antihypertensive agents from complementary classes to achieve BP control,<sup><xref ref-type="bibr" rid="bib10">10</xref>, <xref ref-type="bibr" rid="bib11">11</xref>, <xref ref-type="bibr" rid="bib12">12</xref>, <xref ref-type="bibr" rid="bib13">13</xref></sup> and the results from several recent studies indicate that &#x0223c;23&#x02013;54&#x00025; of patients with hypertension require three or more agents.<sup><xref ref-type="bibr" rid="bib10">10</xref>, <xref ref-type="bibr" rid="bib14">14</xref>, <xref ref-type="bibr" rid="bib15">15</xref>, <xref ref-type="bibr" rid="bib16">16</xref>, <xref ref-type="bibr" rid="bib17">17</xref></sup> Results were recently reported for the first large-scale, randomized, double-blind clinical trial designed to compare the effectiveness and safety of once-daily triple therapy with the calcium channel blocker amlodipine (Aml), the angiotensin receptor antagonist valsartan (Val) and the thiazide diuretic hydrochlorothiazide (HCTZ) (10/320/25&#x02009;mg) versus component-based dual therapy with Val/HCTZ, Aml/Val or Aml/HCTZ for the treatment of moderate to severe hypertension.<sup><xref ref-type="bibr" rid="bib18">18</xref></sup> The results of this study showed that triple therapy with Aml/Val/HCTZ was well tolerated and was significantly more effective in reducing mean sitting SBP (MSSBP) and mean sitting DBP (MSDBP) and in providing BP control than component-based dual therapy. The current article reports the results of ABPM in a subgroup of patients who participated in this triple-therapy study. The objective was to determine the effectiveness of triple therapy for controlling BP throughout the 24-h interval.</p></sec><sec sec-type="methods"><title>Methods</title><p>This study was a randomized, double-blind, parallel-group, active-control trial conducted in 15 countries. The study design, patient selection criteria and disposition of all patients enrolled were reported in detail by Calhoun <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib18">18</xref></sup></p><sec><title>Study treatment</title><p>The study included an antihypertensive washout period and single-blind, placebo run-in period of up to 4 weeks, followed by an 8-week, double-blind treatment period (<xref ref-type="fig" rid="fig1">Figure 1</xref>). At the end of the placebo run-in period, patients were randomly assigned (1:1:1:1) to receive triple therapy with Aml/Val/HCTZ (10/320/25&#x02009;mg) or dual therapy with Val/HCTZ (320/25&#x02009;mg), Aml/Val (10/320&#x02009;mg) or Aml/HCTZ (10/25&#x02009;mg). Randomization was achieved using a validated, interactive, voice-response system. As shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>, the study design included a two-step dose-escalation period in the triple-therapy arm and a single-step dose-escalation period in each of the dual-therapy arms over the first 2 weeks, followed by 6 weeks of treatment at full dosage administered once-daily at 8 . On study visit days, patients were instructed not to take their study medication until assessments were completed.</p></sec><sec><title>Patients</title><p>Patients 18&#x02013;85 years of age with moderate or severe hypertension (grade 2 or 3 or stage 2;<sup><xref ref-type="bibr" rid="bib19">19</xref>, <xref ref-type="bibr" rid="bib20">20</xref></sup> MSSBP &#x02a7e;145 and &#x0003c;200&#x02009;mm&#x02009;Hg and MSDBP &#x02a7e;100 and &#x0003c;120&#x02009;mm&#x02009;Hg) were eligible to participate. Patients were excluded if, at screening, they were receiving four or more antihypertensive agents; three antihypertensive agents and had an MSSBP/MSDBP &#x02a7e;140/90&#x02009;mm&#x02009;Hg; two antihypertensive agents and had an MSSBP/MSDBP &#x02a7e;180/110&#x02009;mm&#x02009;Hg; or no antihypertensive agents and had an MSSBP/MSDBP &#x0003c;140/90&#x02009;mm&#x02009;Hg. Other key exclusion criteria included significant cardiovascular, hepatic, and renal disease and concomitant type 1 diabetes or uncontrolled type 2 diabetes, as previously described.<sup><xref ref-type="bibr" rid="bib18">18</xref></sup></p><p>Patients meeting the screening criteria were immediately randomly assigned to receive treatment if MSSBP was &#x02a7e;180&#x02009;mm&#x02009;Hg or MSDBP was &#x02a7e;110&#x02009;mm&#x02009;Hg. The remaining patients were randomly assigned to receive treatment after a placebo run-in period of up to 4 weeks if MSSBP was &#x02a7e;145&#x02009;mm&#x02009;Hg and MSDBP was &#x02a7e;100&#x02009;mm&#x02009;Hg. Patients were removed from the study if they experienced MSSBP &#x02a7e;200&#x02009;mm&#x02009;Hg or MSDBP &#x02a7e;120&#x02009;mm&#x02009;Hg at any time during the study.</p></sec><sec><title>Efficacy assessments</title><p>The MSSBP and MSDBP measurements were obtained at each study visit, as reported by Calhoun <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib18">18</xref></sup> Per protocol, 24-h ABPM was conducted at baseline before randomization (week 1) and after 8 weeks of double-blind treatment (week 9) in a subset of patients enrolled in the study. Patients were fitted on the non-dominant arm with a Spacelabs 90207 ABPM device (Spacelabs Healthcare Supplies, Issaquah, WA, USA) between 0700 hours and 1000 hours on the first day of each monitoring period, and the device was calibrated to within &#x000b1;7&#x02009;mm&#x02009;Hg against the mean of three DBP readings.<sup><xref ref-type="bibr" rid="bib21">21</xref></sup> Pressure cuffs were set to inflate every 20&#x02009;min over a 24-h time period and to deflate at a rate of 8&#x02009;mm&#x02009;Hg per 2 heartbeats. The ABPM device was removed on the second or third day of each period after a minimum of 24&#x02009;h, and the ABPM data were downloaded and evaluated on site using study-specific ABPM software (Medifacts International, Rockville, MD, USA). If the ABPM data did not meet pre-specified quality control criteria, the entire ABPM procedure could be repeated at the discretion of the study investigator.</p></sec><sec><title>Statistical analyses</title><p>The primary efficacy variables were change from baseline in MSSBP and MSDBP at week 9, as described by Calhoun <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib18">18</xref></sup> Secondary end points reported herein included the change from baseline in 24-h, daytime (0600 hours to 2200 hours) and night time (2200 hours to 0600 hours) mean ambulatory SBP (MASBP) and mean ambulatory DBP (MADBP). Mean 24-h ABPM data from the intent-to-treat population were analyzed using an analysis of covariance model for repeated measures with treatment, region and postdosing hour as factors, baseline 24-h mean ABPM results as a covariate, and treatment by postdosing-hour interactions. Daytime and night time ABPM data from the intent-to-treat population were analyzed using an analysis of covariance model for repeated measures with treatment, region and time (daytime, night time) as factors, baseline 24-h mean ABPM results as a covariate, and treatment-by-time interactions. The mean changes from baseline in MASBP and MADBP (with 95&#x00025; confidence intervals) were assessed at week 9. The differences in the mean changes from baseline in MASBP and MADBP between the triple-therapy arm and the dual-therapy arms were estimated using least squares mean data. MASBP and MADBP at each hour were summarized at baseline and end point for each treatment group.</p><p>Further, <italic>post hoc</italic> analyses of morning (0600 hours to 2400 hours) MASBP and MADBP were individually performed using an analysis of covariance model with treatment and region as factors and baseline 24-h mean ABPM results as a covariate.</p><p>Multiplicity adjustment for <italic>P-</italic>values from the analyses of primary efficacy variables was described by Calhoun <italic>et al.</italic><sup><xref ref-type="bibr" rid="bib18">18</xref></sup> No multiplicity adjustment was made for <italic>P</italic>-values from the analyses of ABPM data.</p><p>Additionally, <italic>post hoc</italic> summary statistics were performed to assess the mean reductions in 24-h ambulatory BP (ABP) in patients grouped according to the severity of hypertension at baseline as assessed by clinic SBP (&#x02a7e;140 and &#x0003c;160&#x02009;mm&#x02009;Hg; &#x02a7e;160 and &#x0003c;200&#x02009;mm&#x02009;Hg; &#x02a7e;180 and &#x0003c;200&#x02009;mm&#x02009;Hg).</p></sec></sec><sec><title>Results</title><sec><title>Baseline characteristics of the patients undergoing ABPM</title><p>Of the 4285 patients enrolled, 2271 were assigned to double-blind treatment and 2060 (90.7&#x00025;) completed treatment,<sup><xref ref-type="bibr" rid="bib18">18</xref></sup> including all 283 patients who underwent 24-h ABPM. The demographic and baseline characteristics of the subgroup of patients undergoing ABPM were similar between treatment arms (<xref rid="tbl1" ref-type="table">Table 1</xref>), and similar to those of the study population as a whole.<sup><xref ref-type="bibr" rid="bib18">18</xref></sup> Of the patients undergoing ABPM, baseline MSSBP/MSDBP was 165.2/105.2&#x02009;mm&#x02009;Hg and MASBP/MADBP was 148.2/93.4&#x02009;mm&#x02009;Hg.</p></sec><sec><title>Changes from baseline in MASBP and MADBP</title><p>All four treatments resulted in clinically relevant and statistically significant reductions from baseline in least squares MASBP and MADBP over the 24-h dosing period and during the daytime and night time hours (<xref ref-type="fig" rid="fig2">Figure 2</xref>; <italic>P</italic>&#x0003c;0.0001 versus baseline for all comparisons). However, the improvements in 24-h, daytime and night time ABP were greatest in patients receiving Aml/Val/HCTZ (<italic>P</italic>&#x02a7d;0.01 for all comparisons). Among the patients receiving triple therapy, the 24-h MASBP decreased by 30.3&#x02009;mm&#x02009;Hg (95&#x00025; confidence interval: &#x02212;31.7, &#x02212;28.8) and the 24-h MADBP decreased by 19.7&#x02009;mm&#x02009;Hg (95&#x00025; confidence interval: &#x02212;20.7, &#x02212;18.7). Consistent results were observed for the daytime and night time hours.</p><p>The absolute 24-h, daytime and night time MASBP/MADBP levels at study end point were lowest in the triple-therapy group (119/75, 123/78 and 111/68&#x02009;mm&#x02009;Hg, respectively).</p></sec><sec><title>Hourly ABP over the 24-h dosing period</title><p>Mean hourly ABPM data obtained at baseline and at week 9 are presented in <xref ref-type="fig" rid="fig3">Figure 3</xref>. At baseline, MASBP levels were &#x0003e;130&#x02009;mm&#x02009;Hg and MADBP levels were &#x0003e;80&#x02009;mm&#x02009;Hg at all time points throughout the 24-h dosing period in all treatment groups. At the end of the study (week 9), all (100&#x00025;) of the hourly MASBP levels were &#x02a7d;130&#x02009;mm&#x02009;Hg in the Aml/Val/HCTZ group. In comparison, 91.7, 83.3 and 41.7&#x00025; of the hourly MASBP levels were &#x0003c;130&#x02009;mm&#x02009;Hg in the Val/HCTZ, Aml/Val and Aml/HCTZ groups, respectively. All hourly end point MADBP levels were &#x0003c;85&#x02009;mm&#x02009;Hg in the triple-therapy group and 87.5&#x00025; (21 of 24) of the hourly levels were &#x0003c;80&#x02009;mm&#x02009;Hg.</p></sec><sec><title>Changes from baseline in early morning MASBP and MADBP</title><p>Statistically significant greater reductions from baseline in morning MASBP and MADBP were observed in patients receiving triple therapy (30.2/20.6&#x02009;mm&#x02009;Hg) compared with Val/HCTZ (24.5/15.7&#x02009;mm&#x02009;Hg; <italic>P</italic>&#x0003c;0.01), Val/Aml (24.6/15.4&#x02009;mm&#x02009;Hg; <italic>P</italic>&#x0003c;0.01) and HCTZ/Aml (19.7/12.4&#x02009;mm&#x02009;Hg; <italic>P</italic>&#x0003c;0.0001). MASBP/MADBP between 0600 hours and 1200 hours was 124/80&#x02009;mm&#x02009;Hg in the triple-therapy group.</p></sec><sec><title>24-h ABP by severity of hypertension at baseline</title><p>Reductions in 24-h MASBP were greater across all treatment groups in the subgroups of patients with baseline MSSBP &#x02a7e;160 and &#x0003c;200&#x02009;mm&#x02009;Hg or baseline MSSBP &#x02a7e;180 and &#x0003c;200&#x02009;mm&#x02009;Hg, compared with the reductions in patients with baseline MSSBP &#x02a7e;140 and &#x0003c;160&#x02009;mm&#x02009;Hg (<xref ref-type="fig" rid="fig4">Figure 4</xref>). In patients with baseline MSSBP &#x02a7e;160 and &#x0003c;200&#x02009;mm&#x02009;Hg or and patients with baseline MSSBP &#x02a7e;180 and &#x0003c;200&#x02009;mm&#x02009;Hg, decreases in MASBP were greater with Aml/Val/HCTZ (34.2 and 37.0&#x02009;mm&#x02009;Hg, respectively) than with dual therapy (range: 21.0&#x02013;26.4 and 22.5&#x02013;31.2&#x02009;mm&#x02009;Hg, respectively). Similarly, decreases in MASBP in patients with baseline MSSBP &#x02a7e;140 and &#x0003c;160&#x02009;mm&#x02009;Hg were also greater with triple therapy than with dual therapy.</p></sec></sec><sec><title>Discussion</title><p>This is the first large-scale, controlled trial to prospectively study the effects of once-daily triple therapy with Aml/Val/HCTZ versus component-based dual therapy for controlling ABP throughout the 24-h interval. The ABPM data from this subgroup of patients corroborate the clinic BP findings from the entire study population.<sup><xref ref-type="bibr" rid="bib18">18</xref></sup> Overall, the ABPM data show that treatment with Aml/Val/HCTZ lowered MASBP/MADBP by &#x0223c;30/20&#x02009;mm&#x02009;Hg throughout the 24-h period, which was significantly better than the reductions achieved in patients receiving dual therapy. An even greater improvement in MASBP (reductions of 37&#x02009;mm&#x02009;Hg) was observed among triple-therapy patients with severe systolic hypertension at baseline (MSSBP &#x02a7e;180 and &#x0003c;200&#x02009;mm&#x02009;Hg).</p><p>The results from the current study further show that the reductions in ABP are relatively uniform throughout the 24-h dosing period. Notably, at end point, hourly MASBP/MADBP levels among patients receiving Aml/Val/HCTZ remained &#x02a7d;130/85&#x02009;mm&#x02009;Hg for every hour of the 24-h dosing period, including the early morning hours. MASBP/MADBP between 0600 hours and 1200 hours, the hours coinciding with the morning surge in BP, was 124/80&#x02009;mm&#x02009;Hg in the triple-therapy group. The ABP levels achieved with triple therapy are clinically relevant considering the 24-h, daytime and night time means were lower than the lower end of the European Society of Hypertension/European Society of Cardiology SBP/DBP target goal ranges for ABP (125&#x02013;130/80, 130&#x02013;135/85 and 120/70&#x02009;mm&#x02009;Hg, respectively).<sup><xref ref-type="bibr" rid="bib20">20</xref></sup></p><p>The results from this ABPM subgroup analysis, in conjunction with the results from the primary efficacy analysis,<sup><xref ref-type="bibr" rid="bib18">18</xref></sup> have important implications for the management of patients with moderate to severe hypertension. The consistent reductions in ABP observed in this study throughout the 24-h dosing interval are important, because ABP has been shown to be a strong predictor of cardiovascular morbidity and mortality.<sup><xref ref-type="bibr" rid="bib22">22</xref>, <xref ref-type="bibr" rid="bib23">23</xref></sup> Moreover, ABPM over 24&#x02009;h is the most accurate method of assessing the effectiveness of antihypertensive therapy<sup><xref ref-type="bibr" rid="bib24">24</xref></sup> and can characterize BP during the early morning hours, when cardiovascular and cerebrovascular events are most likely to occur.<sup><xref ref-type="bibr" rid="bib2">2</xref></sup> At the same time, however, there is a lack of evidence that controlling the morning BP surge translates into a reduction in cardiovascular events.<sup><xref ref-type="bibr" rid="bib25">25</xref></sup> Nonetheless, attaining 24-h BP control is a goal of antihypertensive therapy. In this regard, several studies (including the recently completed effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension (EVALUATE) study<sup><xref ref-type="bibr" rid="bib26">26</xref></sup>) have shown that dual therapy with angiotensin receptor blockers in combination with a non-renin-angiotensin-aldosterone system antihypertensive agent is effective for controlling ABP throughout the day, including the high-risk hours coinciding with the morning surge in BP.<sup><xref ref-type="bibr" rid="bib27">27</xref>, <xref ref-type="bibr" rid="bib28">28</xref>, <xref ref-type="bibr" rid="bib29">29</xref>, <xref ref-type="bibr" rid="bib30">30</xref>, <xref ref-type="bibr" rid="bib31">31</xref>, <xref ref-type="bibr" rid="bib32">32</xref></sup> The results from this study show that additional improvements in ABP can be achieved throughout the day, including the morning hours, with angiotensin receptor blocker-based triple therapy that incorporates agents with complementary mechanisms of action.</p><p>Our study excluded individuals who were on four or more antihypertensive agents. This exclusion may have led to a greater percentage of patients responding to triple therapy as well as dual therapy in our study. However, for ethical reasons, it was not considered appropriate to enroll patients who were in need of four or more antihypertensive agents because the trial only allowed for a maximum of three drugs per patient. As with all clinical trials, study entry criteria can limit extrapolation of results to a broader patient population.</p></sec><sec><title>Conclusion</title><p>In patients with moderate to severe hypertension, once-daily therapy with Aml/Val/HCTZ (10/320/25&#x02009;mg) reduces ABP throughout the 24-h dosing interval, including the overall 24-h, daytime and night time periods, to a significantly greater extent than component-based dual therapy. Aml/Val/HCTZ lowers MASBP/MADBP by &#x0223c;30/20&#x02009;mm&#x02009;Hg throughout the day in these patients with even greater reduction observed in those patients with more severe systolic hypertension. Notably, triple therapy with Aml/Val/HCTZ effectively controls MASBP to &#x02a7d;130&#x02009;mm&#x02009;Hg for every hour throughout the day, including early morning hours.</p><p><inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jhh2010115i1.jpg"/></p></sec></body><back><ack><p>We acknowledge Fran Karo, PhD and Michael S McNamara, MS, of Oxford PharmaGenesis, Inc., for their editorial support in the development of this manuscript. This study was funded by Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.</p></ack><fn-group><fn><p>Disclaimer</p><p>The principal investigator and the co-authors made the decision to submit the manuscript for publication and take responsibility for the content.</p></fn><fn><p>This study is registered as clinical trial number NCT00327587.</p></fn></fn-group><notes><p>Yves Lacourci&#x000e8;re and David Calhoun received research funding from Novartis Pharmaceuticals Corporation for the current study. Robert Glazer, Joseph Yen and Nora Crikelair are employees of Novartis Pharmaceuticals Corporation.</p></notes><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millar-Craig</surname><given-names>MW</given-names></name><name><surname>Bishop</surname><given-names>CN</given-names></name><name><surname>Raftery</surname><given-names>EB</given-names></name></person-group><article-title>Circadian variation of blood-pressure</article-title><source>Lancet</source><year>1978</year><volume>1</volume><fpage>795</fpage><lpage>797</lpage></mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gosse</surname><given-names>P</given-names></name><name><surname>Schumacher</surname><given-names>H</given-names></name></person-group><article-title>Early morning blood pressure surge</article-title><source>J Clin Hypertens (Greenwich)</source><year>2006</year><volume>8</volume><fpage>584</fpage><lpage>589</lpage><pub-id pub-id-type="pmid">16896274</pub-id></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lepp&#x000e4;luoto</surname><given-names>J</given-names></name><name><surname>Ruskoaho</surname><given-names>H</given-names></name></person-group><article-title>Atrial natriuretic peptide, renin activity, aldosterone, urine volume and electrolytes during a 24-h sleep-wake cycle in man</article-title><source>Acta Physiol Scand</source><year>1990</year><volume>139</volume><fpage>47</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">2141447</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Veerman</surname><given-names>DP</given-names></name><name><surname>Imholz</surname><given-names>BP</given-names></name><name><surname>Wieling</surname><given-names>W</given-names></name><name><surname>Wesseling</surname><given-names>KH</given-names></name><name><surname>van Montfrans</surname><given-names>GA</given-names></name></person-group><article-title>Circadian profile of systemic hemodynamics</article-title><source>Hypertension</source><year>1995</year><volume>26</volume><fpage>55</fpage><lpage>59</lpage><pub-id pub-id-type="pmid">7607733</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sica</surname><given-names>DA</given-names></name></person-group><article-title>What are the influences of salt, potassium, the sympathetic nervous system, and the renin-angiotensin system on the circadian variation in blood pressure</article-title><source>Blood Press Monit</source><year>1999</year><volume>4</volume><supplement>(Suppl 2</supplement><fpage>S9</fpage><lpage>S16</lpage><pub-id pub-id-type="pmid">10822417</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lamarre-Cliche</surname><given-names>M</given-names></name><name><surname>de Champlain</surname><given-names>J</given-names></name><name><surname>Lacourci&#x000e8;re</surname><given-names>Y</given-names></name><name><surname>Poirier</surname><given-names>L</given-names></name><name><surname>Karas</surname><given-names>M</given-names></name><name><surname>Larochelle</surname><given-names>P</given-names></name></person-group><article-title>Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives</article-title><source>Am J Hypertens</source><year>2005</year><volume>18</volume><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">15691618</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weir</surname><given-names>MR</given-names></name><name><surname>Dzau</surname><given-names>VJ</given-names></name></person-group><article-title>The renin-angiotensin-aldosterone system: a specific target for hypertension management</article-title><source>Am J Hypertens</source><year>1999</year><volume>12</volume><fpage>205S</fpage><lpage>213S</lpage><pub-id pub-id-type="pmid">10619573</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Redon</surname><given-names>J</given-names></name><name><surname>Roca-Cusachs</surname><given-names>A</given-names></name><name><surname>Mora-Macia</surname><given-names>J</given-names></name></person-group><article-title>Uncontrolled early morning blood pressure in medicated patients: the ACAMPA study. Analysis of the control of blood pressure using ambulatory blood pressure monitoring</article-title><source>Blood Press Monit</source><year>2002</year><volume>7</volume><fpage>111</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">12048428</pub-id></mixed-citation></ref><ref id="bib9"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pol&#x000f3;nia</surname><given-names>J</given-names></name><name><surname>Alcant&#x000e2;ra</surname><given-names>P</given-names></name><name><surname>Amado</surname><given-names>P</given-names></name><name><surname>Silva</surname><given-names>JA</given-names></name><name><surname>Nazar&#x000e9;</surname><given-names>J</given-names></name><name><surname>Braz-Nogueira</surname><given-names>J</given-names></name><etal/></person-group><article-title>Lack of adequate blood pressure control in the morning and evening periods in medicated hypertensive patients considered to be controlled in the office</article-title><source>Rev Port Cardiol</source><year>2005</year><volume>24</volume><fpage>1059</fpage><lpage>1072</lpage><pub-id pub-id-type="pmid">16335281</pub-id></mixed-citation></ref><ref id="bib10"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cushman</surname><given-names>WC</given-names></name><name><surname>Ford</surname><given-names>CE</given-names></name><name><surname>Cutler</surname><given-names>JA</given-names></name><name><surname>Margolis</surname><given-names>KL</given-names></name><name><surname>Davis</surname><given-names>BR</given-names></name><name><surname>Grimm</surname><given-names>RH</given-names></name><etal/></person-group><article-title>Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)</article-title><source>J Clin Hypertens (Greenwich)</source><year>2002</year><volume>4</volume><fpage>393</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">12461301</pub-id></mixed-citation></ref><ref id="bib11"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahl&#x000f6;f</surname><given-names>B</given-names></name><name><surname>Devereux</surname><given-names>RB</given-names></name><name><surname>Kjeldsen</surname><given-names>SE</given-names></name><name><surname>Julius</surname><given-names>S</given-names></name><name><surname>Beevers</surname><given-names>G</given-names></name><name><surname>de Faire</surname><given-names>U</given-names></name><etal/></person-group><article-title>Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol</article-title><source>Lancet</source><year>2002</year><volume>359</volume><fpage>995</fpage><lpage>1003</lpage><pub-id pub-id-type="pmid">11937178</pub-id></mixed-citation></ref><ref id="bib12"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Black</surname><given-names>HR</given-names></name><name><surname>Elliott</surname><given-names>WJ</given-names></name><name><surname>Grandits</surname><given-names>G</given-names></name><name><surname>Grambsch</surname><given-names>P</given-names></name><name><surname>Lucente</surname><given-names>T</given-names></name><name><surname>White</surname><given-names>WB</given-names></name><etal/></person-group><article-title>Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial</article-title><source>JAMA</source><year>2003</year><volume>289</volume><fpage>2073</fpage><lpage>2082</lpage><pub-id pub-id-type="pmid">12709465</pub-id></mixed-citation></ref><ref id="bib13"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milani</surname><given-names>RV</given-names></name></person-group><article-title>Reaching for aggressive blood pressure goals: role of angiotensin receptor blockade in combination therapy</article-title><source>Am J Manag Care</source><year>2005</year><volume>11</volume><supplement>(7 Suppl</supplement><fpage>S220</fpage><lpage>S227</lpage><pub-id pub-id-type="pmid">16180960</pub-id></mixed-citation></ref><ref id="bib14"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></name><name><surname>Bakris</surname><given-names>G</given-names></name><name><surname>Greene</surname><given-names>T</given-names></name><name><surname>Agodoa</surname><given-names>LY</given-names></name><name><surname>Appel</surname><given-names>LJ</given-names></name><name><surname>Charleston</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial</article-title><source>JAMA</source><year>2002</year><volume>288</volume><fpage>2421</fpage><lpage>2431</lpage><pub-id pub-id-type="pmid">12435255</pub-id></mixed-citation></ref><ref id="bib15"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pepine</surname><given-names>CJ</given-names></name><name><surname>Handberg</surname><given-names>EM</given-names></name><name><surname>Cooper-DeHoff</surname><given-names>RM</given-names></name><name><surname>Marks</surname><given-names>RG</given-names></name><name><surname>Kowey</surname><given-names>P</given-names></name><name><surname>Messerli</surname><given-names>FH</given-names></name><etal/></person-group><article-title>A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial</article-title><source>JAMA</source><year>2003</year><volume>290</volume><fpage>2805</fpage><lpage>2816</lpage><pub-id pub-id-type="pmid">14657064</pub-id></mixed-citation></ref><ref id="bib16"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bangalore</surname><given-names>S</given-names></name><name><surname>Messerli</surname><given-names>FH</given-names></name><name><surname>Cohen</surname><given-names>JD</given-names></name><name><surname>Bacher</surname><given-names>PH</given-names></name><name><surname>Sleight</surname><given-names>P</given-names></name><name><surname>Mancia</surname><given-names>G</given-names></name><etal/></person-group><article-title>Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy</article-title><source>Am Heart J</source><year>2008</year><volume>156</volume><fpage>241</fpage><lpage>247</lpage><pub-id pub-id-type="pmid">18657652</pub-id></mixed-citation></ref><ref id="bib17"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jamerson</surname><given-names>K</given-names></name><name><surname>Weber</surname><given-names>MA</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><name><surname>Dahl&#x000f6;f</surname><given-names>B</given-names></name><name><surname>Pitt</surname><given-names>B</given-names></name><name><surname>Shi</surname><given-names>V</given-names></name><etal/></person-group><article-title>Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>2417</fpage><lpage>2428</lpage><pub-id pub-id-type="pmid">19052124</pub-id></mixed-citation></ref><ref id="bib18"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Calhoun</surname><given-names>DA</given-names></name><name><surname>Lacourci&#x000e8;re</surname><given-names>Y</given-names></name><name><surname>Chiang</surname><given-names>YT</given-names></name><name><surname>Glazer</surname><given-names>RD</given-names></name></person-group><article-title>Triple antihypertensive therapy with amlodipine, valsartan, and hydrochlorothiazide: a randomized clinical trial</article-title><source>Hypertension</source><year>2009</year><volume>54</volume><fpage>32</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">19470877</pub-id></mixed-citation></ref><ref id="bib19"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chobanian</surname><given-names>AV</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><name><surname>Black</surname><given-names>HR</given-names></name><name><surname>Cushman</surname><given-names>WC</given-names></name><name><surname>Green</surname><given-names>LA</given-names></name><name><surname>Izzo</surname><given-names>JL</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure</article-title><source>Hypertension</source><year>2003</year><volume>42</volume><fpage>1206</fpage><lpage>1252</lpage><pub-id pub-id-type="pmid">14656957</pub-id></mixed-citation></ref><ref id="bib20"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>De Backer</surname><given-names>G</given-names></name><name><surname>Dominiczak</surname><given-names>A</given-names></name><name><surname>Cifkova</surname><given-names>R</given-names></name><name><surname>Fagard</surname><given-names>R</given-names></name><name><surname>Germano</surname><given-names>G</given-names></name><etal/></person-group><article-title>2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)</article-title><source>J Hypertens</source><year>2007</year><volume>25</volume><fpage>1105</fpage><lpage>1187</lpage><pub-id pub-id-type="pmid">17563527</pub-id></mixed-citation></ref><ref id="bib21"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>B</given-names></name><name><surname>Poulter</surname><given-names>NR</given-names></name><name><surname>Brown</surname><given-names>MJ</given-names></name><name><surname>Davis</surname><given-names>M</given-names></name><name><surname>McInnes</surname><given-names>GT</given-names></name><name><surname>Potter</surname><given-names>JF</given-names></name><etal/></person-group><article-title>British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary</article-title><source>BMJ</source><year>2004</year><volume>328</volume><fpage>634</fpage><lpage>640</lpage></mixed-citation></ref><ref id="bib22"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ommen</surname><given-names>ES</given-names></name><name><surname>Lipkowitz</surname><given-names>MS</given-names></name></person-group><article-title>The role of ambulatory BP monitoring in clinical care</article-title><source>Geriatrics</source><year>2007</year><volume>62</volume><fpage>11</fpage><lpage>14</lpage></mixed-citation></ref><ref id="bib23"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conen</surname><given-names>D</given-names></name><name><surname>Bamberg</surname><given-names>F</given-names></name></person-group><article-title>Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis</article-title><source>J Hypertens</source><year>2008</year><volume>26</volume><fpage>1290</fpage><lpage>1299</lpage><pub-id pub-id-type="pmid">18550999</pub-id></mixed-citation></ref><ref id="bib24"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Staessen</surname><given-names>JA</given-names></name><name><surname>Beilin</surname><given-names>L</given-names></name><name><surname>Parati</surname><given-names>G</given-names></name><name><surname>Waeber</surname><given-names>B</given-names></name><name><surname>White</surname><given-names>W</given-names></name></person-group><article-title>Task force IV: clinical use of ambulatory blood pressure monitoring. Participants of the 1999 Consensus Conference on ambulatory blood pressure monitoring</article-title><source>Blood Press Monit</source><year>1999</year><volume>4</volume><fpage>319</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">10602536</pub-id></mixed-citation></ref><ref id="bib25"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>WB</given-names></name></person-group><article-title>Importance of blood pressure control over a 24-hour period</article-title><source>J Manag Care Pharm</source><year>2007</year><volume>13</volume><supplement>(8 Suppl B</supplement><fpage>34</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">17970615</pub-id></mixed-citation></ref><ref id="bib26"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacourci&#x000e8;re</surname><given-names>Y</given-names></name><name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></name><name><surname>Samuel</surname><given-names>R</given-names></name><name><surname>Zappe</surname><given-names>D</given-names></name><name><surname>Purkayastha</surname><given-names>D</given-names></name><name><surname>Black</surname><given-names>HR</given-names></name></person-group><article-title>Effects of force-titrated valsartan/hydrochlorothiazide versus amlodipine/hydrochlorothiazide on ambulatory blood pressure in patients with stage 2 hypertension: the EVALUATE study</article-title><source>Blood Press Monit</source><year>2009</year><volume>14</volume><fpage>112</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">19384192</pub-id></mixed-citation></ref><ref id="bib27"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacourci&#x000e8;re</surname><given-names>Y</given-names></name><name><surname>Gil-Extremera</surname><given-names>B</given-names></name><name><surname>Mueller</surname><given-names>O</given-names></name><name><surname>Byrne</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>L</given-names></name></person-group><article-title>Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension</article-title><source>Int J Clin Pract</source><year>2003</year><volume>57</volume><fpage>273</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">12800457</pub-id></mixed-citation></ref><ref id="bib28"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacourci&#x000e8;re</surname><given-names>Y</given-names></name><name><surname>Neutel</surname><given-names>JM</given-names></name><name><surname>Schumacher</surname><given-names>H</given-names></name></person-group><article-title>Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5&#x02009;mg and 80/12.5&#x02009;mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5&#x02009;mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials</article-title><source>Clin Ther</source><year>2005</year><volume>27</volume><fpage>1795</fpage><lpage>1805</lpage><pub-id pub-id-type="pmid">16368450</pub-id></mixed-citation></ref><ref id="bib29"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neutel</surname><given-names>JM</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name></person-group><article-title>Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension</article-title><source>J Int Med Res</source><year>2005</year><volume>33</volume><fpage>620</fpage><lpage>631</lpage><pub-id pub-id-type="pmid">16372579</pub-id></mixed-citation></ref><ref id="bib30"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neldam</surname><given-names>S</given-names></name><name><surname>Edwards</surname><given-names>C</given-names></name></person-group><article-title>Telmisartan plus HCTZ vs. amlodipine plus HCTZ in older patients with systolic hypertension: results from a large ambulatory blood pressure monitoring study</article-title><source>Am J Geriatr Cardiol</source><year>2006</year><volume>15</volume><fpage>151</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">16687967</pub-id></mixed-citation></ref><ref id="bib31"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minami</surname><given-names>J</given-names></name><name><surname>Abe</surname><given-names>C</given-names></name><name><surname>Akashiba</surname><given-names>A</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><name><surname>Kameda</surname><given-names>T</given-names></name><name><surname>Ishimitsu</surname><given-names>T</given-names></name><etal/></person-group><article-title>Long-term efficacy of combination therapy with losartan and low-dose hydrochlorothiazide in patients with uncontrolled hypertension</article-title><source>Int Heart J</source><year>2007</year><volume>48</volume><fpage>177</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">17409583</pub-id></mixed-citation></ref><ref id="bib32"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>AM</given-names></name><name><surname>Davidson</surname><given-names>J</given-names></name><name><surname>Koval</surname><given-names>S</given-names></name><name><surname>Lacourci&#x000e8;re</surname><given-names>Y</given-names></name></person-group><article-title>Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study</article-title><source>Cardiovasc Diabetol</source><year>2007</year><volume>6</volume><fpage>28</fpage><pub-id pub-id-type="pmid">17910747</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p>Study design.<sup><xref ref-type="bibr" rid="bib18">18</xref></sup> Aml, amlodipine; HCTZ, hydrochlorothiazide; Val, valsartan.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jhh2010115f1"/></fig><fig id="fig2"><label>Figure 2</label><caption><p>Least squares mean change from baseline in 24-h, daytime and night time ambulatory (<bold>a</bold>) SBP and (<bold>b</bold>) DBP. Hexagons represent baseline values and circles represent end point values. Dotted lines indicate the upper end of the European Society of Hypertension/European Society of Cardiology target ranges for MASBP/MADBP (24&#x02009;h: 125&#x02013;130/80&#x02009;mm&#x02009;Hg; daytime: 130&#x02013;135/85&#x02009;mm&#x02009;Hg; night time: 120/70&#x02009;mm&#x02009;Hg).<sup><xref ref-type="bibr" rid="bib20">20</xref></sup> <sup>&#x0002a;</sup><italic>P</italic>&#x02a7d;0.0001 versus Aml/Val/HCTZ; <sup>&#x0002a;&#x0002a;</sup><italic>P</italic>&#x02a7d;0.001 versus Aml/Val/HCTZ; <sup>&#x0002a;&#x0002a;&#x0002a;</sup><italic>P</italic>&#x02a7d;0.01 versus Aml/Val/HCTZ. Aml, amlodipine; ESH/ESC, European Society of Hypertension/European Society of Cardiology; HCTZ, hydrochlorothiazide; MADBP, mean ambulatory diastolic blood pressure; MASBP, mean ambulatory systolic blood pressure; Val, valsartan.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jhh2010115f2"/></fig><fig id="fig3"><label>Figure 3</label><caption><p>Hourly MASBP (<bold>a</bold>) and MADBP (<bold>b</bold>) at baseline and end point over the 24-h dosing interval. Dotted lines indicate the upper end of the European Society of Hypertension/European Society of Cardiology target range for mean 24-h MASBP/MADBP (125&#x02013;130/80&#x02009;mm&#x02009;Hg).<sup><xref ref-type="bibr" rid="bib20">20</xref></sup> Aml, amlodipine; ESH/ESC, European Society of Hypertension/European Society of Cardiology; HCTZ, hydrochlorothiazide; MADBP, mean ambulatory diastolic blood pressure; MASBP, mean ambulatory systolic blood pressure; Val, valsartan.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jhh2010115f3"/></fig><fig id="fig4"><label>Figure 4</label><caption><p>Change from baseline in 24-h MASBP according to the severity of hypertension at baseline. Hexagons represent baseline values and circles represent end point values. Dotted line indicates the upper end of the European Society of Hypertension/European Society of Cardiology target range for mean 24-h MASBP (125&#x02013;130&#x02009;mm&#x02009;Hg).<sup><xref ref-type="bibr" rid="bib20">20</xref></sup> Aml, amlodipine; ESH/ESC, European Society of Hypertension/European Society of Cardiology; HCTZ, hydrochlorothiazide; MASBP, mean ambulatory systolic blood pressure; MSSBP, mean sitting systolic blood pressure; Val, valsartan.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jhh2010115f4"/></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Baseline demographics and patient characteristics for the subgroup of patients undergoing 24-h ambulatory BP monitoring</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/><col align="char" char="("/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><italic>Characteristic</italic></th><th align="center" valign="top" char="(" charoff="50"><italic>Aml/HCTZ (10/25&#x02009;mg) (</italic>n=<italic>76)</italic></th><th align="center" valign="top" char="(" charoff="50"><italic>Aml/Val (10/320&#x02009;mg) (</italic>n=<italic>71)</italic></th><th align="center" valign="top" char="(" charoff="50"><italic>Val/HCTZ (320/25&#x02009;mg) (</italic>n=<italic>69)</italic></th><th align="center" valign="top" char="(" charoff="50"><italic>Aml/Val/HCTZ 10/320/25&#x02009;mg (</italic>n=<italic>67)</italic></th></tr></thead><tbody valign="top"><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Sex, n</italic> (&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Male</td><td align="char" valign="top" char="(" charoff="50">42 (55.3)</td><td align="char" valign="top" char="(" charoff="50">40 (56.3)</td><td align="char" valign="top" char="(" charoff="50">40 (58.0)</td><td align="char" valign="top" char="(" charoff="50">42 (62.7)</td></tr><tr><td align="left" valign="top" charoff="50"><italic>Age, mean (s.d.), years</italic></td><td align="char" valign="top" char="(" charoff="50">55.5 (8.9)</td><td align="char" valign="top" char="(" charoff="50">53.6 (9.3)</td><td align="char" valign="top" char="(" charoff="50">53.0 (8.5)</td><td align="char" valign="top" char="(" charoff="50">54.1 (9.9)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Age group, n</italic> (&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;&#x02a7e;65 years</td><td align="char" valign="top" char="(" charoff="50">16 (21.1)</td><td align="char" valign="top" char="(" charoff="50">9 (12.7)</td><td align="char" valign="top" char="(" charoff="50">5 (7.2)</td><td align="char" valign="top" char="(" charoff="50">10 (14.9)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Race, n</italic> (&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;White</td><td align="char" valign="top" char="(" charoff="50">60 (78.9)</td><td align="char" valign="top" char="(" charoff="50">54 (76.1)</td><td align="char" valign="top" char="(" charoff="50">56 (81.2)</td><td align="char" valign="top" char="(" charoff="50">54 (80.6)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Black</td><td align="char" valign="top" char="(" charoff="50">14 (18.4)</td><td align="char" valign="top" char="(" charoff="50">12 (16.9)</td><td align="char" valign="top" char="(" charoff="50">10 (14.5)</td><td align="char" valign="top" char="(" charoff="50">10 (14.9)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Other</td><td align="char" valign="top" char="(" charoff="50">2 (2.6)</td><td align="char" valign="top" char="(" charoff="50">5 (7.0)</td><td align="char" valign="top" char="(" charoff="50">3 (4.4)</td><td align="char" valign="top" char="(" charoff="50">3 (4.5)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Ethnicity, n</italic> (&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Hispanic/Latino</td><td align="char" valign="top" char="(" charoff="50">13 (17.1)</td><td align="char" valign="top" char="(" charoff="50">8 (11.3)</td><td align="char" valign="top" char="(" charoff="50">13 (18.8)</td><td align="char" valign="top" char="(" charoff="50">9 (13.4)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;Non-Hispanic/Latino</td><td align="char" valign="top" char="(" charoff="50">63 (82.9)</td><td align="char" valign="top" char="(" charoff="50">63 (88.7)</td><td align="char" valign="top" char="(" charoff="50">56 (81.2)</td><td align="char" valign="top" char="(" charoff="50">58 (86.6)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50"><italic>BMI, mean (s.d.), kg&#x02009;m<sup>&#x02212;2</sup></italic></td><td align="char" valign="top" char="(" charoff="50">30.9 (4.7)</td><td align="char" valign="top" char="(" charoff="50">30.8 (4.7)</td><td align="char" valign="top" char="(" charoff="50">32.0 (5.6)</td><td align="char" valign="top" char="(" charoff="50">31.2 (5.2)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Sitting BP, mean (</italic>s.d.<italic>), mm</italic>&#x02009;<italic>Hg</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;SBP</td><td align="char" valign="top" char="(" charoff="50">164.6 (13.5)</td><td align="char" valign="top" char="(" charoff="50">166.3 (13.5)</td><td align="char" valign="top" char="(" charoff="50">164.4 (12.2)</td><td align="char" valign="top" char="(" charoff="50">165.6 (13.3)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;DBP</td><td align="char" valign="top" char="(" charoff="50">105.5 (4.4)</td><td align="char" valign="top" char="(" charoff="50">105.0 (4.4)</td><td align="char" valign="top" char="(" charoff="50">104.9 (5.0)</td><td align="char" valign="top" char="(" charoff="50">105.4 (3.9)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>24-h ambulatory BP, mean (</italic>s.d.<italic>), mm</italic>&#x02009;<italic>Hg</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;SBP</td><td align="char" valign="top" char="(" charoff="50">147.3 (13.1)</td><td align="char" valign="top" char="(" charoff="50">149.7 (14.2)</td><td align="char" valign="top" char="(" charoff="50">146.4 (13.5)</td><td align="char" valign="top" char="(" charoff="50">149.6 (13.4)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;DBP</td><td align="char" valign="top" char="(" charoff="50">93.4 (9.4)</td><td align="char" valign="top" char="(" charoff="50">93.1 (8.1)</td><td align="char" valign="top" char="(" charoff="50">92.8 (9.1)</td><td align="char" valign="top" char="(" charoff="50">94.4 (10.0)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Severity of baseline systolic HTN, n</italic> (&#x00025;)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;MSSBP &#x02a7e;140 and &#x0003c;160&#x02009;mm&#x02009;Hg</td><td align="char" valign="top" char="(" charoff="50">33 (43.4)</td><td align="char" valign="top" char="(" charoff="50">26 (36.6)</td><td align="char" valign="top" char="(" charoff="50">26 (37.7)</td><td align="char" valign="top" char="(" charoff="50">31 (46.3)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;MSSBP &#x02a7e;160 and &#x0003c;200&#x02009;mm&#x02009;Hg</td><td align="char" valign="top" char="(" charoff="50">43 (56.6)</td><td align="char" valign="top" char="(" charoff="50">45 (63.4)</td><td align="char" valign="top" char="(" charoff="50">43 (62.3)</td><td align="char" valign="top" char="(" charoff="50">36 (53.7)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;MSSBP &#x02a7e;180 and &#x0003c;200&#x02009;mm&#x02009;Hg</td><td align="char" valign="top" char="(" charoff="50">12 (15.8)</td><td align="char" valign="top" char="(" charoff="50">15 (12.1)</td><td align="char" valign="top" char="(" charoff="50">7 (10.1)</td><td align="char" valign="top" char="(" charoff="50">11 (16.4)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td><td align="char" valign="top" char="(" charoff="50">&#x000a0;</td></tr><tr><td colspan="5" align="left" valign="top" charoff="50"><italic>Baseline SBP, mean (</italic>s.d.<italic>), mm&#x02009;Hg</italic></td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;MSSBP &#x02a7e;140 and &#x0003c;160&#x02009;mm&#x02009;Hg</td><td align="char" valign="top" char="(" charoff="50">153.1 (4.1)</td><td align="char" valign="top" char="(" charoff="50">152.9 (4.5)</td><td align="char" valign="top" char="(" charoff="50">151.6 (4.2)</td><td align="char" valign="top" char="(" charoff="50">154.1 (4.4)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;MSSBP &#x02a7e;160 and &#x0003c;200&#x02009;mm&#x02009;Hg</td><td align="char" valign="top" char="(" charoff="50">173.4 (11.4)</td><td align="char" valign="top" char="(" charoff="50">174.1 (10.4)</td><td align="char" valign="top" char="(" charoff="50">172.1 (8.3)</td><td align="char" valign="top" char="(" charoff="50">175.5 (9.9)</td></tr><tr><td align="left" valign="top" charoff="50">&#x02003;MSSBP &#x02a7e;180 and &#x0003c;200&#x02009;mm&#x02009;Hg</td><td align="char" valign="top" char="(" charoff="50">189.2 (6.3)</td><td align="char" valign="top" char="(" charoff="50">186.9 (6.3)</td><td align="char" valign="top" char="(" charoff="50">185.4 (5.1)</td><td align="char" valign="top" char="(" charoff="50">187.5 (5.1)</td></tr></tbody></table><table-wrap-foot><fn id="t1-fn1"><p>Abbreviations: Aml, amlodipine; BMI, body mass index; BP, blood pressure; DBP, diastolic BP; HCTZ, hydrochlorothiazide; HTN, hypertension; MSSBP, mean sitting SBP; SBP, systolic BP; s.d., standard deviation; Val, valsartan.</p></fn></table-wrap-foot></table-wrap></floats-group></article>